Ziprasidone augmentation of clozapine in 11 patients [2]

Journal of Clinical Psychiatry

Volumn 64, Issue 2, 2003, Pages 215-216

  Kaye, Neil S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ZIPRASIDONE;

ADULT; ANTICHOLINERGIC EFFECT; APATHY; BODY WEIGHT DISORDER; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; LETTER; LONG QT SYNDROME; MALE; MOTIVATION; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 0037328230     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0215b     Document Type: Letter

References (10)

1. Pies R. Combining antipsychotics: risks and benefits. Int Drug Ther Newsletter 2001;36:9-13
2. Taylor D, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000;101:416-432
3. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapinequetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999;18:99-104
4. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(suppl 10):31-41
5. Geodon [package insert]. New York, NY: Pfizer Pharmaceuticals; 2001
6. Schmidt A. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201
7. Keck P. Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother 2001;2:1033-1042
8. Tandon R. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics. Br J Clin Pharmacol 2000;49(suppl 1):1-3
9. Kapur S. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia, Annu Rev Med 2001;52:503-517
10. Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999;44:235-244